Vanda Preps sNDA for HETLIOZ in Insomnia
Vanda’s trial results of HETLIOZ (tasimelteon) for insomnia suggest that circadian misalignment may be the etiology behind chronic primary insomnia for many patients.
Category: Prescription Drugs
Prescription Drugs
Latest
Prescription Drugs
LatestNSAIDS May Limit Passage of Narcolepsy Medication Gamma Hydroxybutyric Acid to the Brain
Previous studies completed by the UB researchers found that the NSAIDs ibuprofen and ketoprofen also affected the movement of GHB in the body.
Prescription Drugs
Latest
WAKIX Time-to-Onset & Cardiovascular Safety Data Presented at AAN 2021
"These analyses further characterize the efficacy and safety profile of WAKIX and its broad clinical utility for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy."
Jazz Pharmaceuticals Shares Results from Sleep Medicine Research & Therapy Development
Thirteen abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021.
Read More
Long-Term Use of Prescription Meds for Insomnia Not Linked to Better Quality Sleep
There was no difference in sleep quality or duration between those who did and didn’t take these meds for 1 to 2 years, the findings show.
Read MoreWAKIX Data Presented to Mental Health Professionals at APA Annual Meeting
Sleep disorders are highly comorbid with a multitude of psychiatric disorders and narcolepsy can have a significant impact on a person’s daily functioning, which may greatly affect their social, emotional and psychological well-being, and quality of life.
Read More
Jazz Pharmaceuticals Presents Phase 3 Results of Xywav in Idiopathic Hypersomnia
The AAN presentation further quantifies the previously reported Phase 3 top-line results.
Read More
What Region Is Most Associated with Fracture-Associated Prescription Drug Use?
Many commonly prescribed drugs—such as some sleep aids—are known to carry an increased risk of breaking a bone, by increasing falls, weakening bones, or both.
Read MoreTeva Raises Price for Nuvigil
Reuters: The hikes could help make up for lost revenue as doctors visits and new prescriptions plummeted during the global lockdown.
Read More
What We Know About Narcolepsy, Sodium Oxybate Use, Salt Intake & Cardiovascular Risk
A literature review from Stanford University looks at how the popular narcolepsy medication sodium oxybate impacts heart health.
Read More
Z-Drugs Have Similar or Greater Adverse Events in Dementia Patients as Benzos
Researchers studied the adverse events for 3,532 patients who had been prescribed Z-drugs and compared them to people with sleep disturbance who had not been prescribed sedatives and with patients who had been prescribed benzodiazepines.
Read MoreEuropean Commission Fines Teva & Cephalon for Delaying Entry of Generic Modafinil
The commission investigation has found that for several years, this “pay-for-delay” agreement eliminated Teva as a competitor and allowed Cephalon to continue charging high prices even if the main modafinil patent had long expired.
Read MoreFDA Approves HETLIOZ for Sleep Disturbances in Smith-Magenis Syndrome
Smith-Magenis Syndrome is a rare neurodevelopmental disorder, a defining feature of which is an “inverted” circadian rhythm.
Read More
Insomnia Patient Survey Offers Some Answers on Prescription Drug Use
Health Union, which creates condition-specific online patient communities, shared results from its Sleep Disorders In America survey.
Read More
Expanded WAKIX Label Could ‘Help Even More People Living with Narcolepsy’
The FDA says that Harmony Biosciences’ drug—previously approved for excessive daytime sleepiness in narcolepsy—works for cataplexy too. Harmony’s chief medical officer explains how this impacts healthcare practitioners and patients.
Read More
Xywav Phase 3 Data Published in SLEEP
Results of the double-blind, placebo-controlled, randomized-withdrawal, multicenter study were previously presented at World Sleep 2019.
Read More
WAKIX Gets Additional FDA Approval—for Cataplexy
FDA approval of WAKIX for the treatment of cataplexy in adult patients with narcolepsy is based on two randomized, controlled trials.
Read More
Drugs Aren’t Typically Tested on Women. AI Could Correct That Bias.
Though men and women can have different responses to medications—Ambien, for example, metabolizes more slowly in women, causing next-day grogginess—doctors may not know about these differences because most clinical trial data are biased toward men.
Read More